Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02355535 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | completed | Phase 1 | 48 | Vanquish Oncology, Inc.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT02575300 | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04129255 | Octreotide LAR in the Induction of Immunologic Response in NENs Patients(CSMS99) | completed | Phase 2 | 34 | National Cancer Institute, NaplesOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT03883776 | Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors | completed | Phase 1 | 12 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03562091 | Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel(OPERA) | completed | — | 115 | IpsenINDUSTRY | 1 | Aug 28, 2020 | clinicaltrials |
| NCT02402062 | A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours | completed | Phase 2 | 17 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03197012 | Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor | completed | Early Phase 1 | 10 | Thomas HopeOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02730104 | Community-based Neuroendocrine Tumor (NET) Research Study | completed | — | 100 | IpsenINDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT04440956 | An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours | completed | Early Phase 1 | 10 | Clarity Pharmaceuticals LtdINDUSTRY | 0 | Jun 22, 2020 | clinicaltrials |
| NCT02067988 | Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study(HEPAR_Plus) | completed | Phase 2 | 34 | UMC UtrechtOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04425954 | Evaluation of Early Retinal Vascular Modifications After Endoscopic Endonasal Pituitary Surgery | completed | — | 14 | Federico II UniversityOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT02788565 | Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours(STREET) | completed | — | 156 | IpsenINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03112694 | Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors | completed | — | 93 | IpsenINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03840720 | The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET | completed | — | 20 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 28, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00171873 | Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut | completed | Phase 3 | 85 | Carmen Schade-BrittingerOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT02841865 | Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria(CRIPNET) | completed | — | 104 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT01970540 | Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | completed | Phase 1 | 122 | PharmaMarINDUSTRY | 2 | Mar 9, 2020 | clinicaltrials |
| NCT04296149 | Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe(RADIONET) | completed | Phase 2 | 5 | European Institute of OncologyOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00939523 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | completed | Phase 2 | 9 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00501540 | Lithium for Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02357498 | Transsphenoidal Extent of Resection Study(TRANSSPHER) | completed | N/A | 260 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02727686 | Post-Operative Water Load Following Transsphenoidal Pituitary Surgery | completed | N/A | 30 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT01967537 | Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors | completed | Phase 2 | 341 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01476592 | A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors | completed | N/A | 7 | University of Wisconsin, MadisonOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02125474 | Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate | completed | N/A | 39 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Nov 14, 2019 | clinicaltrials |
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01456078 | A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors(ILUMINET) | completed | Phase 2 | 60 | Lund University HospitalOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT00781911 | A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 20, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT03167853 | Study of JS001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 40 | Peking UniversityOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT02075606 | Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients(CALM-NET) | completed | Phase 4 | 50 | IpsenINDUSTRY | 1 | Jun 7, 2019 | clinicaltrials |
| NCT01280201 | Pazopanib as Single Agent in Advanced NETs | completed | Phase 2 | 44 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT03948841 | Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences(NETMRI) | completed | — | 41 | CHU de ReimsOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT02231762 | Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET(SONNET) | completed | Phase 2 | 57 | IpsenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT01283542 | Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.(Passion I) | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2019 | clinicaltrials |
| NCT01590199 | Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs(MACS2002) | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT00605566 | Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors | completed | Phase 2 | 22 | University Health Network, TorontoOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00688623 | RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe(RAMSETE/CDE16) | completed | Phase 2 | 73 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 25, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | completed | Phase 1 / Phase 2 | 68 | Arbutus Biopharma CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01840449 | Somatuline Predictive Factors in Acromegaly and NET(SOPRANo) | completed | — | 156 | IpsenINDUSTRY | 3 | Jan 14, 2019 | clinicaltrials |
| NCT00747786 | Non Interventional Post Marketing Programme in Neuroendocrine Tumours | completed | — | 40 | IpsenINDUSTRY | 1 | Jan 7, 2019 | clinicaltrials |
| NCT03017690 | Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | completed | — | 22 | IpsenINDUSTRY | 1 | Dec 21, 2018 | clinicaltrials |
| NCT03220087 | Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain(RECOSY) | completed | — | 142 | IpsenINDUSTRY | 1 | Dec 21, 2018 | clinicaltrials |
| NCT02267967 | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors | completed | Phase 1 | 81 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 13, 2018 | clinicaltrials |
| NCT00037869 | High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors | completed | Phase 3 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Sep 24, 2020source: clinicaltrials